In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Bookmark
  • Analysis

Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials

By Bridget Silverman

The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.

Drug Approval Standards Rare Diseases
Bookmark
  • Analysis

EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review

By Derrick Gingery
Labeling changes for the multiple sclerosis drug being mandated by European regulators were made to the US label in January.
Neurology Drug Safety
Bookmark
  • Interviews

South Korea's ADEL Innovates With Anti-Tau Antibody For Alzheimer’s Disease

By Jung Won Shin

Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.

South Korea Neurology
Bookmark
  • Analysis

2018 Saw Record Launches, But No Big Splash

By Jessica Merrill

The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.

Launches Growth
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Biogen Idec Inc.
  • Biogen Inc.
  • Idec Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • Michel Vounatsos, CEO
    Jeffrey Capello, EVP, CFO
    Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
    Michael Ehlers, MD, PhD, EVP, R&D
    Daniel Karp, EVP, Corp. Dev.
    Chirfi Guindo, EVP & Head, Global Mktg.
  • Contact Info
  • Biogen Inc.
    Phone: (617) 679-2000
    225 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By